Vertex Pharmaceuticals Is A Strong Buy

Summary

  • VRTX has earned quite a lot of traction driven by the rapid approval of its triple combo Cystic Fibrosis regimen, Trikafta.
  • VRTX delivered a stellar performance in the third quarter of 2019 primarily driven by substantial demand for its product line.
  • The company is rapidly advancing its product portfolio to include other specialty diseases.

Keeping in mind the proliferation of research in rare disease treatments, biotechnology companies that offer these therapeutics proposes a great alternative for long term investment. Vertex Pharmaceuticals(VRTX) is one such leading company in this space especially noteworthy because of its pipeline potential and capacity to outpace the pharma industry.

With the company's keen focus on cystic fibrosis, a deadly genetic disease with an estimated 75,000 patients worldwide, the VRTX has expanded rapidly and has become one of the industry’s top rare-disease drug firms.

Company Overview

Vertex Pharmaceuticals (VRTX) is a biopharmaceutical company that discovers, develops, and markets therapeutics to treat patients suffering from rare, life-threatening diseases.

Vertex started as a biotech company that worked on researching, developing and licensing several products to large pharmaceutical firms but later on, the company shifted its paradigm to developing and selling its own product line.

Latest Developments

Recently, Vertex Pharmaceuticals settled a conclusive agreement with NHS England allowing it to make all three of its UK-licensed cystic fibrosis drugs accessible to the NHS patients. Although it is understood that a compromise has been made on the cost of the drug, the deal is estimated to benefit almost half of the 10,000 patients in the UK. The deal came just weeks after VRTX reached a five-year agreement with the Scottish government over the use of Orkambi and Symkevi. Additionally, the firm also attained a reimbursement deal for Orkambi and Symdeko in Spain and Australia. These deals could prove significant in propelling revenue growth outside the US in the following quarters.

Trikafta's Rapid Approval

VRTX has earned quite a lot of traction driven by the rapid approval of its triple combo Cystic Fibrosis regimen, Trikafta, which is estimated to cover 90% of the 27,000 CF patients in the country, according to the FDA.

Trikaftacontains a combination of three drugs elexacaftor, tezacaftor and ivacaftor in which elexacaftor is the latest discovery of the company developed to treat the most common form of cystic fibrosis, caused by the F508del mutation. Nearly 90% of all CF patients have at least one copy of this mutation and clinical trial results indicated that patients undertaking this treatment showed considerable improvements in lung function, body mass index, and sweat chloride.

This new drug regimen can be prescribed to CF patients aged 12 years or older and works by correcting the F508del mutated protein. This is a tremendous accomplishment for the company considering that doctors believe this life-threatening disorder might metamorphose into a chronic condition, akin to diabetes.

As highlighted in the latest earnings call, the management firmly believes that revenue growth in 2020 will be heavily influenced by the Trikafta.

READ FULL ARTICLE HERE